How does liraglutide compare to semaglutide?

Both are GLP-1 agonists, but semaglutide is more potent and longer-acting, producing greater weight loss (15-17% vs 5-8%) and allowing weekly rather than daily dosing. Liraglutide has a longer track record and more extensive real-world safety data.

Is liraglutide safe for weight loss?

Liraglutide (Saxenda) is approved and has been used safely for weight management in millions of patients. Common side effects are gastrointestinal. Use should be under medical supervision with appropriate patient selection.

How quickly does liraglutide work?

Effects on appetite often begin within days to weeks. Maximum weight loss typically occurs over 6-12 months with continued use. Blood glucose improvements may be seen within weeks.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

GLP-1 Agonists•Updated 2026-02-01•5 min read

What Is Liraglutide? Benefits, Research & Safety

An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.

Share:X Post LinkedIn

Also known as:

Victoza

Saxenda

NN2211

AStrong human evidenceUK: Prescription-only (UK POM)WADA: Sport status unclear

UK summary: Licensed UK medicine (Saxenda for weight management; Victoza for type 2 diabetes). Prescription-only. Daily injection; pre-dates and is generally less potent than semaglutide and tirzepatide. Lawful supply requires a UK prescriber and a regulated pharmacy.

Quick Facts

Overview

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It was one of the first long-acting GLP-1 analogues, sharing 97% sequence homology with native human GLP-1 but with modifications that extend its duration of action to allow once-daily dosing. Like native GLP-1, liraglutide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. These effects make it effective for both blood glucose management in type 2 diabetes and weight reduction in obesity. Liraglutide is marketed under two brand names: Victoza for type 2 diabetes treatment (at doses up to 1.8 mg daily) and Saxenda for chronic weight management (at 3.0 mg daily). Both formulations require once-daily subcutaneous injection. While semaglutide has since become more prominent due to its greater weight loss efficacy and weekly dosing, liraglutide remains an important option with a longer track record of clinical use and extensive safety data from years of widespread use.

Evidence standards summary

Liraglutide — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

AStrong human evidenceOverall grade against our evidence grading methodology.

Licensed UK medicine (Saxenda for weight management; Victoza for type 2 diabetes). Prescription-only. Daily injection; pre-dates and is generally less potent than semaglutide and tirzepatide. Lawful supply requires a UK prescriber and a regulated pharmacy.

02Human evidence grade

AStrong human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.
EU: EMA approved for both indications.
Notes: Liraglutide is a fully approved prescription medication available through legitimate medical channels.

05Approved medical uses

Type 2 diabetes (Victoza — MHRA-licensed POM).
Chronic weight management in adults with BMI ≥ 30 or ≥ 27 with weight-related comorbidity (Saxenda — MHRA-licensed POM).
Chronic weight management in adolescents aged 12-17 with obesity (Saxenda — MHRA-licensed POM).

06Unapproved / promotional claims

Available without prescription from EU pharmacies.
Same effect as semaglutide for less money.
Safe to self-administer without medical supervision.
Compounded versions are equivalent to the licensed product.

07Common internet claims

Marketed by online sellers as a cheaper Wegovy alternative.
Sold via grey-market routes that bypass UK prescription requirements.
Promoted in 'compounded liraglutide' forms by some online clinics.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Approved by MHRA for weight management”	A	Yes	Low	Liraglutide is licensed in the UK as Saxenda for chronic weight management in eligible patients; Victoza is licensed for type 2 diabetes.
“Same effect as semaglutide for less money”	C	Yes	Moderate	Head-to-head data suggest liraglutide produces less weight loss than semaglutide and requires daily injections rather than weekly.
“Available without prescription from EU pharmacies”	E	No	High	Liraglutide is a UK POM; the UK supply route requires a UK prescription and regulated pharmacy.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

GI side effects (nausea, vomiting, diarrhoea) — common, dose-related.
Pancreatitis (rare; class effect for GLP-1 agonists).
Gallbladder disease (accelerated by rapid weight loss).
Thyroid C-cell tumours (theoretical class warning; rodent finding, uncertain human relevance).

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Prescription-only (UK POM)

MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.

Read the full UK legal guide → Semaglutide and UK law

14EU legal position

EMA approved for both indications.

15What this page cannot tell you

Whether a non-UK-prescription source supplies genuine, properly-stored product.
Whether liraglutide is the right GLP-1 for your particular situation (semaglutide / tirzepatide may be preferred).
Optimal duration and post-discontinuation management.
Whether 'compounded liraglutide' from an online clinic meets sterility and identity standards.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Long-term cardiovascular outcomes beyond LEADER trial endpoints.
Optimal weight-management duration and stopping rules.
Real-world cost-effectiveness against newer GLP-1s in NHS settings.

19Safer alternatives / established care pathways

Licensed Wegovy (semaglutide) or Mounjaro (tirzepatide) via NHS specialist or GMC-registered private prescriber where higher efficacy is required.
Continued lifestyle intervention via NHS Tier 2 weight-management programmes.
Bariatric assessment for patients meeting NICE criteria.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Am I better suited to liraglutide or a weekly GLP-1 such as semaglutide?
What is the dose-escalation schedule and side-effect plan?
Is NHS access realistic for my situation, or is private the route?
How will we monitor progress and when would we stop?
What should I do if I want to stop the medicine?

Discovery & History

Liraglutide was developed by Novo Nordisk in the late 1990s and early 2000s as part of the company's GLP-1 research programme. The development was based on understanding that native GLP-1, while therapeutically promising, was rapidly degraded in the body with a half-life of only 1-2 minutes. The key innovation was the acylation of GLP-1 with a fatty acid chain, enabling the molecule to bind non-covalently to albumin. This dramatically extended its half-life to approximately 13 hours, making once-daily injection practical. Liraglutide received FDA approval for type 2 diabetes (as Victoza) in 2010 and EMA approval followed. It was one of the most successful diabetes drug launches, demonstrating both glycaemic and cardiovascular benefits. In 2014, the FDA approved a higher dose of liraglutide (3.0 mg daily) as Saxenda for chronic weight management. This followed the SCALE clinical trial programme demonstrating significant weight loss in people with obesity. The LEADER cardiovascular outcomes trial, published in 2016, demonstrated that liraglutide reduced the risk of major adverse cardiovascular events in high-risk patients with type 2 diabetes, adding an important benefit to its profile.

Mechanism of Action

Liraglutide activates GLP-1 receptors to produce multiple metabolic effects: **Glucose-Dependent Insulin Secretion** Liraglutide stimulates insulin release from pancreatic beta cells only when blood glucose is elevated, reducing hypoglycaemia risk compared to some other diabetes treatments. **Glucagon Suppression** The peptide inhibits inappropriate glucagon secretion from pancreatic alpha cells, particularly in the postprandial state, improving glucose control. **Gastric Emptying Delay** Liraglutide slows the rate at which food leaves the stomach, contributing to improved post-meal glucose levels and enhanced feelings of fullness. **Central Appetite Suppression** GLP-1 receptors in the hypothalamus and brainstem mediate appetite-reducing effects. Liraglutide reduces hunger and promotes satiety, leading to decreased caloric intake. **Cardiovascular Effects** Through mechanisms not fully understood but likely involving direct effects on the heart and vasculature as well as improved metabolic parameters, liraglutide provides cardiovascular protection.

Researched Benefits

Based on preclinical and clinical research findings:

1
Improved glycaemic control with HbA1c reductions of 1-1.5%
2
Weight loss averaging 5-8% of body weight (Saxenda dose)
3
Reduced cardiovascular events in high-risk patients (LEADER trial)
4
Decreased systolic blood pressure
5
Improved beta cell function markers
6
Reduced appetite and food cravings
7
Improved lipid profiles

Claim vs Evidence

How popular claims about Liraglutide stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Approved by MHRA for weight management”	A	Yes	Low	Liraglutide is licensed in the UK as Saxenda for chronic weight management in eligible patients; Victoza is licensed for type 2 diabetes.
“Same effect as semaglutide for less money”	C	Yes	Moderate	Head-to-head data suggest liraglutide produces less weight loss than semaglutide and requires daily injections rather than weekly.
“Available without prescription from EU pharmacies”	E	No	High	Liraglutide is a UK POM; the UK supply route requires a UK prescription and regulated pharmacy.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Diabetes: 0.6-1.8 mg daily; Obesity: up to 3.0 mg daily
Frequency	Once daily subcutaneous injection
Duration	Long-term treatment; gradual dose escalation over several weeks
Notes	Liraglutide is a prescription medication requiring medical supervision. Doses are typically escalated gradually to minimise gastrointestinal side effects.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection (once daily)

Half-Life	Stability
Approximately 13 hours	Pens should be refrigerated before first use; can be kept at room temperature for up to 30 days after first use

Safety Profile & Known Risks

Commonly Reported Side Effects

Nausea (especially during initiation)
Vomiting
Diarrhoea
Constipation
Headache
Decreased appetite
Injection site reactions

Rare Risks & Concerns

Pancreatitis
Gallbladder disease
Thyroid tumours (based on rodent studies)
Hypoglycaemia (especially with concurrent insulin or sulfonylureas)
Acute kidney injury

Contraindications

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2
History of pancreatitis
Pregnancy and breastfeeding
Type 1 diabetes

UK & EU Regulatory Context

🇬🇧 United Kingdom

MHRA approved. Victoza for type 2 diabetes; Saxenda for weight management.

🇪🇺 European Union

EMA approved for both indications.

Liraglutide is a fully approved prescription medication available through legitimate medical channels.

Clinical Studies Summary

LEADER: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Demonstrated 13% reduction in major adverse cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.

N Engl J Med. 2016View on PubMed

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Showed 8% weight loss with liraglutide 3.0 mg vs 2.6% with placebo over 56 weeks.

N Engl J Med. 2015View on PubMed

Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis.

For individuals with normal weight, both semaglutide and liraglutide are generally more effective for treating T2DM. However, considering the potential for semaglutide to cause hypoglycemia, liraglutide may be the optimal choice for T2DM treatment to minimize the risk of hypoglycemia.

Sci Rep. 2025View on PubMed

Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.

GLP- 1 agonists such as liraglutide and semaglutide effectively lower body weight and BMI in patients who suffer from weight recurrence or suboptimal clinical response after undergoing MBS. However, future studies are still warranted to investigate the most appropriate protocols for management.

Obes Surg. 2025View on PubMed

Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis.

GLP-1 RAs showed several adverse gastrointestinal effects in non-diabetic patients with overweight or obesity. Understanding the different risk profiles of GLP-1 RAs helps clinicians make informed treatment decisions by balancing therapeutic benefits with potential side effects.

Int J Obes (Lond). 2025View on PubMed

Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis.

Using GLP-1 RA is a safe and effective treatment for weight regain and insufficient weight loss after MBS.

Obes Rev. 2024View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 4

Approved product

Yes

Liraglutide

35 of 66 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

PHASE1

Status: Recruiting · 75 participants · Novo Nordisk A/S

Conditions: Obesity

No results postedNCT07225816

Tirzepatide vs Liraglutide in Bone

N/A

Status: Recruiting · 72 participants · National and Kapodistrian University of Athens

Conditions: Obesity (Disorder)

No results postedNCT07094568

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

PHASE4

Status: Recruiting · 430 participants · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions: T2DM (Type 2 Diabetes Mellitus)

No results postedNCT07244003

Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

Status: Completed · 10 participants · Nils Opel

Conditions: Healthy

No results postedNCT06818292

LIROH - Liraglutide for Obesity in HIV

PHASE4

Status: Unknown · 40 participants · Brigham and Women's Hospital

Conditions: Obesity, HIV Infections

No results postedNCT06438146

The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

PHASE4

Status: Unknown · 256 participants · Peking University People's Hospital

Conditions: Diabetes Mellitus, Type 2

No results postedNCT06408532

Research on Timing of Liraglutide Therapy in Patients With Obesity After Metabolic Surgery

PHASE4

Status: Completed · 100 participants · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Conditions: Obesity, Weight Loss, Bariatric Surgery

No results postedNCT07374445

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

PHASE1

Status: Completed · 32 participants · Carmot Therapeutics, Inc.

Conditions: Type 1 Diabetes

No results postedNCT05794581

A Study of LY3537021 in Healthy Participants

PHASE1

Status: Completed · 47 participants · Eli Lilly and Company

Conditions: Healthy

No results postedNCT05444569

Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus

PHASE3

Status: Completed · 35 participants · David Sanchez Garcia

Conditions: Diabetes Mellitus, Type 1

No results postedNCT05467514

Use of a GLP-1R Agonist to Treat Opioid Use Disorder

PHASE1/PHASE2

Status: Completed · 27 participants · Milton S. Hershey Medical Center

Conditions: Opiate Substitution Treatment, Opioid-Related Disorders

Results postedNCT04199728

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

N/A

Status: Completed · 241,981 participants · Kaiser Permanente

Conditions: Type 2 Diabetes Mellitus, Cardiovascular Diseases

Results postedNCT05073692

Adverse event reports (FDA FAERS)

nausea647
vomiting331
dyspnoea328
blood glucose increased326
diarrhoea321
anxiety228
pancreatitis219
condition aggravated216
headache215
drug ineffective209

FDA FAERS spontaneous reports. A report is not proof the substance caused the event, and an absence of reports is not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Liraglutide?

Source research-grade Liraglutide from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Liraglutide

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Am I better suited to liraglutide or a weekly GLP-1 such as semaglutide?
What is the dose-escalation schedule and side-effect plan?
Is NHS access realistic for my situation, or is private the route?
How will we monitor progress and when would we stop?
What should I do if I want to stop the medicine?

UK regulatory & safety context

Semaglutide and UK law

UK legal reference

Prescription-only medicines

Safety Centre guide

Related Research Guides

Peptides for Fat Loss

Read guide

Related Peptides

Semaglutide

A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.

Learn more

GLP-1

A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.

Learn more

Explore More Peptides

Browse our comprehensive database of research-backed peptide profiles.